Stockscreener 앱 받기
3.23
1.89%
0.06
시간 외 거래:
3.28
0.05
+1.55%
전일 마감가:
$3.17
열려 있는:
$3.14
하루 거래량:
3.40M
Relative Volume:
0.77
시가총액:
$526.68M
수익:
$296.15M
순이익/손실:
$24.02M
주가수익비율:
26.78
EPS:
0.1206
순현금흐름:
$127.01M
1주 성능:
-4.44%
1개월 성능:
-29.93%
6개월 성능:
+129.08%
1년 성능:
+116.78%
1일 변동 폭
$3.055
$3.26
1주일 범위
$3.05
$3.52
52주 변동 폭
$0.5271
$5.78
아이언우드 제약 Stock (IRWD) Company Profile
명칭
Ironwood Pharmaceuticals Inc
전화
617-621-7722
주소
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.23 | 516.89M | 296.15M | 24.02M | 127.01M | 0.1206 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
아이언우드 제약 Stock (IRWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-08 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Wells Fargo | Overweight |
| 2023-11-09 | 개시 | Jefferies | Buy |
| 2023-09-28 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-02 | 개시 | CapitalOne | Overweight |
| 2022-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 개시 | Northland Capital | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-11-07 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 개시 | H.C. Wainwright | Sell |
| 2018-05-09 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2017-07-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 개시 | Wells Fargo | Outperform |
| 2017-04-07 | 재확인 | Mizuho | Buy |
| 2017-02-22 | 재확인 | Barclays | Equal Weight |
| 2016-11-04 | 재확인 | Mizuho | Buy |
| 2016-10-24 | 재확인 | Wedbush | Neutral |
| 2016-10-10 | 재확인 | Mizuho | Buy |
| 2016-09-27 | 재확인 | WallachBeth | Hold |
모두보기
아이언우드 제약 주식(IRWD)의 최신 뉴스
Aug Rallies: Is Ironwood Pharmaceuticals Inc affected by consumer sentiment2026 Trade Ideas & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Pullback Watch: How much upside does Ironwood Pharmaceuticals Inc have2026 Intraday Action & Weekly High Return Stock Forecasts - baoquankhu1.vn
Insider Selling: Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Sells 6,730,800 Shares of Stock - MarketBeat
Ironwood Pharmaceuticals director Denner sells $20.5m in shares - Investing.com
Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale - Stock Titan
Breakouts Watch: Is Ironwood Pharmaceuticals Incs growth already priced in2026 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Up 15.8% in February - MarketBeat
Trade Report: Can Ironwood Pharmaceuticals Inc outperform in the next rallyWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - MSN
Ironwood Pharmaceuticals (IRWD) CLO receives 136,612-share RSU grant - Stock Titan
Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant - Stock Titan
Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award - Stock Titan
Ironwood (IRWD) SVP and CMO awarded 136,612-share RSU performance grant - Stock Titan
Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award - Stock Titan
Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award - Stock Titan
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - TradingView
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail
Ironwood Pharma Maintains Revolving Credit Facility to 2028 - The Globe and Mail
Ironwood Pharmaceuticals, Inc. 8-K SEC Filing Details – Company Information, Address, and Nasdaq Listing - Minichart
Ironwood Pharmaceuticals confirms liquidity conditions for credit facility maturity - Investing.com
Ironwood Pharmaceuticals confirms liquidity conditions for credit facility maturity By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals Satisfies Liquidity Conditions In Credit Agreement On March 10 - TradingView
Ironwood Pharmaceuticals, Inc. Notifies Wells Fargo Bank, National Association of Satisfaction of Liquidity Conditions Under Amended Credit Agreement - marketscreener.com
Ironwood (NASDAQ: IRWD) confirms revolving credit facility maturity in 2028 - Stock Titan
Investment Review: Can Ironwood Pharmaceuticals Inc stock double in the next yearJuly 2025 Price Swings & Weekly High Momentum Picks - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Aug Reactions: Will Ironwood Pharmaceuticals Inc outperform the market in YEAR2025 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? - Yahoo Finance
Ironwood Pharma Stock Quote, Share Price, News and Analysis - Longbridge
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - PharmiWeb.com
US Stocks Recap: Does Ironwood Pharmaceuticals Inc have declining or rising EPSJuly 2025 Catalysts & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Gains Report: Can Ironwood Pharmaceuticals Inc stock double in the next yearPrice Action & Target Return Focused Stock Picks - baoquankhu1.vn
IRWD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
IRWD Should I Buy - Intellectia AI
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 10.1%Time to Sell? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to "Hold" at Zacks Research - MarketBeat
Jefferies Maintains Hold on Ironwood Pharmaceuticals (IRWD) Feb 26, 2026 - Meyka
A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance - Yahoo Finance
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide - Seeking Alpha
Jefferies raises Ironwood Pharmaceuticals stock price target on Linzess outlook - Investing.com Canada
IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks - Finviz
IRWD: Analyst Raises Price Target and Maintains Rating | IRWD St - GuruFocus
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 9.5% on Analyst Upgrade - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target Raised to $10.00 at Citizens Jmp - MarketBeat
GSA Capital Partners LLP Has $405,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (IRWD) Margin Rebound Challenges Bearish Narratives Despite Softer Revenue - simplywall.st
Ironwood (IRWD) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ironwood Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
아이언우드 제약 (IRWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아이언우드 제약 주식 (IRWD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| John Minardo | Chief Legal Officer |
Feb 24 '26 |
Sale |
3.66 |
19,053 |
69,734 |
363,886 |
| John Minardo | Chief Legal Officer |
Feb 23 '26 |
Sale |
3.81 |
17,439 |
66,443 |
382,939 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 23 '26 |
Sale |
3.81 |
15,570 |
59,322 |
538,437 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,239 |
41,135 |
213,738 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,287 |
39,193 |
224,977 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 24 '26 |
Sale |
3.66 |
103,526 |
378,905 |
1,489,002 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 23 '26 |
Sale |
3.81 |
94,757 |
361,024 |
1,592,528 |
| Martini Gregory S. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,457 |
41,933 |
160,601 |
| Martini Gregory S. | Chief Financial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,487 |
39,955 |
172,058 |
| Silver Ronald | Principal Accounting Officer |
Feb 24 '26 |
Sale |
3.66 |
12,621 |
46,193 |
252,636 |
2.02%
0.77%
자본화:
|
볼륨(24시간):